Autoimmune disease stories

Jun 26, 2026

European Medicines Agency Recommends Revoking Amgen's Tavneos Over Data Integrity Issues

The European Medicines Agency recommended withdrawing marketing authorization for Amgen's rare autoimmune disease drug Tavneos, citing allegedly incorrect and misleading data used in the approval process and lack of benefits outweighing risks.

Jun 26, 2026·3 sources

Apr 11, 2026

CAR-T Therapy Shows Continued Success in Autoimmune Diseases Five Years After Lupus Breakthrough

Five years after initial lupus breakthrough, CAR-T cell therapy continues to demonstrate remissions in autoimmune diseases, generating significant research investment and experimentation beyond its original cancer applications.

Apr 11, 2026·1 source

Apr 6, 2026

Scripps Research Develops New Anti-Inflammatory Drug Class That Preserves Immune Function

Scripps Research scientists have developed a first-in-class drug compound that reduces harmful inflammation while leaving the body's ability to fight infections intact, addressing a long-sought goal in treating autoimmune diseases.

Apr 6, 2026·1 source

FDA Delay Forces Small Biotech Company to Shut Down Operations

A small biotech company was forced to wind down operations after the FDA abruptly postponed a key meeting for four months, despite reaching a clinical trial agreement in February that came too late.

Apr 6, 2026·2 sources

Top claims

▪Tavneos was originally developed by ChemoCentryx, which Amgen later acquired for $3.7 billion.
▪Amgen stated it was "deeply concerned" about the EMA's recommendation and that it "continues to believe that Tavneos is an important treatment option."
▪Amgen's partner in Europe, CSL Vifor, is leading interactions with the EMA regarding next steps for patients and providers.

Topics

European Union Pharmaceutical Industry Aging biology experts Biomarkers & bloodwork testing Inflammation reduction & immune effects Longevity biotech founders

Related entities

Rare Disease Germany Lupus Inflammation Immunology Rheumatoid arthritis

Featured Stories

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

Aug 7, 2026·2 sources